Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05848518
Other study ID # CampusSantJoan
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 15, 2023
Est. completion date January 31, 2024

Study information

Verified date March 2024
Source Campus docent Sant Joan de Déu-Universitat de Barcelona
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Many patients with COVID-19 present the so-called post-acute sequelae of COVID-19 such as fatigue, post-stress discomfort, dyspnea, headache, pain mental impairment, incapacity to perform daily physical tasks ant exercise intolerance. This study aims to investigate the effects of different exercise programs on physical and mental fitness, physical condition and biomarkers of the immune system and oxidative stress in older COVID-19 survivors. Methods: The sample will be made up of 120 eligible participants, over the age of 60 years who have had COVID-19 disease and are survivors and present persistent COVID-19 symptomatology diagnosed by the corresponding physician. The participants will be randomly assigned to the experimental groups: supervised endurance group (SEG, n = 30), supervised strength group (SSG, n = 30), supervised concurrent group (SCG, n = 30), which will perform the corresponding exercise program 3 days a week compared to the control group (CG, n = 30), which will not carry out a supervised exercise program. The design of this project will include assessment of cardiorespiratory fitness, muscle fitness, pain and mental health, and biomarkers of inflammation and oxidative stress.


Description:

This project will carry out a randomized controlled trial to determine what type of supervised exercise program is the most effective compared with a control group (CG): supervised endurance group (SEG), supervised strength group (SSG), supervised concurrent group (strength and endurance) (SCG) and CG. The project will be divided into 3 subprojects and performed in coordination by three institutions as follows: i) Subproject of the consolidated research group on pain, physical activity, nutrition and health (Acronym: DAFNiS) of the Campus Sant Joan de Deu. University of Barcelona. "Effects of a physical exercise program (aerobic, strength or combined/concurrent) on muscle fitness, pain and mental health in older COVID-19 survivors". ii) Subproject of the Hospital of Matar: "Evaluation of cardiorespiratory and muscular fitness in older COVID-19 survivors". iii) Subproject of the Department of Physiology and Immunology. University of Barcelona. "Evaluation of biomarkers of inflammation and oxidative stress in older COVID-19 survivors". The sample will be made up of 120 eligible participants, over the age of 60 years who have had COVID-19 disease and are survivors and present persistent COVID-19 symptomatology with sequelae of fatigue, muscle weakness, pain, difficulty in performing daily life activities, etc. diagnosed by the corresponding physician. The participants will be recruited from Hospital of Matar. Candidates fulfilling the study inclusion criteria will provide signed informed consent prior to inclusion. To calculate the sample size of this project a type 1 (α) error of 5% and a 95% confidence interval with a level of precision (d = 0.095) was established for the test of proportional hypotheses resulting in a sample size of n= 108 persons, increased by 10% (rounded up to n=120) to compensate for possible dropouts along the study period. To know the sample size more precisely in the hypothesis test of means it will be necessary to carry out a pilot study which will provide the size of effect and statistical power (0.80), determine the analysis to perform, obtain delta values in the units corresponding to the principal study variable as well as know the standard deviation. Program of supervised exercise The intervention will consist in a program of supervised physical exercise performed 3 times a week for 12 weeks. For the planning and control of the exercise program the progressive individualized planning model will be applied based on the subjective perception of effort and cardiorespiratory parameters (heart rate and ventilatory threshold determined in the evaluation tests) of the participants. This program has been used by our research group in previous studies for improving cardiorespiratory and muscle fitness. The basis of this periodization model establishes an initial period of individualization to obtain the personal parameters used for the training load The COVID-19 survivors will be randomly assigned to 3 programs of supervised exercise : 1. Program of endurance exercise. The program of supervised endurance exercise will consist in walking for 1 hour 3 times a week. The intensity (step speed) will gradually be increased each week (approx. 5%) according to the perception of the participant. A pulsometer will be used to determine the safe range of heart rate at which the participant should perform. 2. Program of strength exercise This will consist in performing a program of traditional strength 1 hour 3 times a week. Circuit training methodology will be used (10 exercises) alternating muscle groups of the upper and lower extremities and trunk. The initial series be of 1 exercise, evolving to up to 3-4 along the program based on the individual adaptation of the individual. The intensity (load applied) will be gradually increased each week while the recovery times between each exercise activity will be reduced (approx. 5%) according to the perception of the participant. A pulsometer will be used to determine the safe range of heart rate at which the participant should perform. 3. Program of concurrent exercise (endurance and strength) The participants will perform 1 hour of concurrent exercise, combining walking (20 minutes) and the strength program for 40 minutes, maintaining the same instructions explained previously in each exercise program. 4. Control group The control group will not carry out any supervised exercise program but will maintain their same habits of daily life activities. Process of evaluation To determine the effects of the exercise program, an initial evaluation will be made before beginning the exercise program to assess the initial status of the participants (Pre). This evaluation will be compared with the evaluation made at the end of the intervention program (Post) at 12 weeks


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date January 31, 2024
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Persons of both sexes (and different expression of gender) older than 60 years of age. - No history of physical diseases and no disease or disability that limits participation in the exercise program or precludes the corresponding measurement/evaluations. - Be able to communicate without difficulty. - Be able to understand the objectives of the project and provide informed consent. In this case, the consent form will be signed. - Not taking any medication that can affect normal performance of the exercise program and the evaluations Exclusion Criteria: - Having acute or terminal disease or any other disease that may affect the normal practice of a supervised exercise program and the corresponding evaluations. - Consumption of alcohol or drugs. - Be performing any type of activity that may interfere in carrying out the supervised exercise program or the evaluations. - Not completing the study once initiated or wishing to participate in the control group.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Rehabilitation program
The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)

Locations

Country Name City State
Spain Campus Docent Sant Joan de Déu. Universitat de Barcelona Sant Boi De Llobregat Barcelona

Sponsors (3)

Lead Sponsor Collaborator
Campus docent Sant Joan de Déu-Universitat de Barcelona Hospital de Mataró, University of Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiorespiratory fitness: absolute oxygen uptake absolute oxygen uptake (peak VO2) in L/min 1 week per group
Primary Cardiorespiratory fitness: relative oxygen uptake relative oxygen uptake (peak VO2) in mL/kg/min 1 week per group
Primary Cardiorespiratory fitness: ventilation minute ventilation (VE) in L/min. 1 week per group
Primary Cardiorespiratory fitness: ventilatory equivalent for oxygen Ventilatory equivalent for oxygen (VE/VO2) 1 week per group
Primary Cardiorespiratory fitness: ventilatory equivalent for carbon dioxide Ventilatory equivalent for carbon dioxide (VE/VCO2) 1 week per group
Primary Cardiorespiratory fitness: respiratory exchange ratio Respiratory exchange ratio (RER) 1 week per group
Primary Cardiorespiratory fitness: End-tidal partial pressure End-tidal partial pressure of oxygen and carbon dioxide (PetO2 and PetCO2, respectively) in mmHg. 1 week per group
Primary Muscular fitness: Sit and stand test Sit and stand test for 30 seconds. The number of times in 30 seconds the participant can completely stand up from a seated position with the back straight and the feet on the floor without pushing with the arms will be counted. 1 week per group
Primary Muscular fitness: countermovement jump Countermovement jumps: Flight Height in cm 1 week per group
Primary Muscular fitness: countermovement test Countermovement jumps: power output of the lower extremities in watts 1 week per group
Primary Muscular fitness: Upper limb strength This will be evaluated with the bicep curl test made with a 2 kg weight for women and a 4 Kg weight for men. The number of elbow curls made in 30 seconds with each upper limb will be counted. 1 week per group
Primary Muscular fitness: hand grip strength Hand grip strength: Force in Newtons Motor Agility/Dynamic balance: This will be evaluated with the 8-foot up and go test. The best of two attempts will be registered 1 week per group
Primary Muscular fitness: Motor Agility/Dynamic balance Motor Agility/Dynamic balance: This will be evaluated with the 8-foot up and go test. The best of two attempts will be registered in seconds 1 week per group
Primary Muscular fitness: Isokinetic strength test The isokinetic knee flexor and extensor test: peak torque in N m 1 week per group
Primary Muscular fitness: Isokinetic strength testing The isokinetic knee flexor and extensor test: power output in Watts 1 week per group
Primary Body composition: fat mass Fat mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight. 1 week per group
Primary Body composition: fat free mass Fat free mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight. 1 week per group
Primary Body composition: muscle mass Muscle mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight. 1 week per group
Primary Concentration of oxidative stress biomarkers: thiobarbituric acid reactive substances Determination of oxidized lipids by the thiobarbituric acid reactive substances (TBARS) in mmols (fluorimetry technique). 1 week per group
Primary Concentration of oxidative stress biomarkers: Advanced Oxidation Protein Products Determination of oxidized proteins by the Advanced Oxidation Protein Products (AOPP) in nmol Cl-T/mg protein, (colorimetry technique) 1 week per group
Primary Concentration of oxidative stress biomarkers: nitrites and nitrates Determination of nitrites and nitrates (colorimetry) in nmol/mL 1 week per group
Primary Concentration of biomarkers of antioxidant enzymes: superoxide dismutase superoxide dismutase (SOD) in units/mL 1 week per group
Primary Concentration of biomarkers of antioxidant enzymes: catalase catalase (CAT) in units/mL 1 week per group
Primary Concentration of biomarkers of antioxidant enzymes: glutathion peroxidase Glutathion peroxidase (GPx) in units/mL. 1 week per group
Primary Concentration of inflammation biomarkers: Interleukines Interleukin 6 and 10 (IL-6 and IL-10) in ng/mL 1 week per group
Primary Concentration of inflammation biomarkers: adiponectin adiponectin in mg/L 1 week per group
Primary Concentration of biomarkers of inflammation: Tumor necrosis factor Tumor Necrosis Factor-alpha in pg/mL 1 week per group
Primary Evaluation of the degree of pain using the pupillometer: pupil diameter basal and maximum diameter of the pupil in mm 1 week per group
Primary Evaluation of the degree of pain using the pupillometer:variation of pupil percentage of variation of pupil diameter in % 1 week per group
Primary Evaluation of the degree of pain using the pupillometer: pupil variation variation of the pupil in mm 1 week per group
Primary Evaluation of the degree of pain using the pupillometer: Intensity of reflex of dilatation Intensity of reflex of dilatation, latency. 1 week per group
Primary Evaluation of the degree of pain with a pressure algometer: algometers Pain will be quantified with a pressure algometer + pupillometer in older COVID-19 survivors.
A pressure algometer allows the application of a controlled and quantifiable nociceptive stimulus on a body surface.
Algometers apply a pressure stimulus that can be useful for applying a standardized painful stimulus, having a different nature from that applied with the pupillometer which is a stimulus of electric origin.
1 week per group
Primary Mental health Psychosocial variables will be evaluated using the Hospital Anxiety and Depression Scale (HADS), which is made up of 7 items for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) will be scored on a scale of 4 points from 0 (none) to 3 (much more). The highest scores indicate the highest levels of anxiety or depression 1 week per group
See also
  Status Clinical Trial Phase
Recruiting NCT05926505 - Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome Phase 2/Phase 3
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Completed NCT05552612 - Health-related Quality of Life and Long COVID
Completed NCT05531019 - COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A N/A
Not yet recruiting NCT04949386 - Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. Phase 2
Recruiting NCT06118112 - Living With Long COVID: LONGCOVID-EXPERIENCE
Completed NCT05185674 - Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
Active, not recruiting NCT05965739 - RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms N/A
Active, not recruiting NCT05965752 - RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms N/A
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT05606211 - Pain in Long COVID-19: The Role of Sleep
Active, not recruiting NCT05713266 - Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
Completed NCT05679505 - Vagus Nerve Stimulation for Post-COVID Syndrome N/A
Completed NCT05601180 - Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID. N/A
Not yet recruiting NCT06045338 - Mind Body Intervention for Long COVID N/A
Recruiting NCT06091358 - Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation. N/A
Recruiting NCT05566392 - Longterm Influence of Pediatric Long COVID Syndrome
Recruiting NCT05855369 - Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss Phase 2/Phase 3
Recruiting NCT05572346 - Digital App for Telerehabilitation in Respiratory Diseases
Recruiting NCT06316843 - Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 Phase 2